What conditions must be met for a screening colonoscopy to be considered reliable? When should a follow-up colonoscopy be performed sooner than indicated by the surveillance schedule and how long after initial examination?
Should patients with neutropenia be screened for aspergillosis, eg, with periodic galactomannan testing? Is a positive galactomannan test result without abnormal radiologic findings an indication to initiate treatment in a patient with neutropenia?
What is the current place of cannabidiol and other cannabinoids in the treatment of epilepsy? How often are OTC cannabinoid preparations used by patients with epilepsy in North America? How does it affect the clinical management of epilepsy?
In view of recent clinical trials, which patients with SLE may benefit most from treatment with a type 1 interferon antagonist? Is the safety profile of this therapy acceptable today, in the era of the mutating SARS-CoV-2 pandemic?